MOUNTAIN VIEW, Calif., Aug. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Canaccord Adams 29th Annual Global Growth Conference in Boston.

The VIVUS presentation will take place at the Intercontinental Hotel on Thursday, August 13, 2009 at 8:30 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://www.wsw.com/webcast/canaccord/vvus or http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:             VIVUS, Inc.
                         Timothy E. Morris
                         Chief Financial Officer
                         +1-650-934-5200
    INVESTOR RELATIONS:  The Trout Group
                         Brian Korb
                         +1-646-378-2923
    MEDIA RELATIONS:     Pure Communications, Inc.
                         Sheryl Seapy
                         +1-949-608-0841

SOURCE VIVUS, Inc.